Alembic Pharmaceuticals quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	2,150	1,711	+25.7%
EBITDA	332	281	+18.0%
EBITDA margin	15.4%	16.5%	−1.0 pts
Profit before tax	221	191	+16.2%
Net profit	172	154	+12.2%
EPS	₹8.80	₹7.85	+12.1%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	2,150	1,848	1,876	1,910	1,711	1,770	1,693	1,648	1,562	1,517	1,631	1,595	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	14.9	25.5	15.5	6.9	6.5	14.2	9.5	16.7	2.1	3.6	2.9	10.2
	2,165	1,873	1,892	1,917	1,717	1,784	1,702	1,665	1,564	1,521	1,633	1,605
	517	404	449	463	431	426	447	393	406	337	318	414
	121	130	143	127	109	92.6	120	103	95.5	111	165	88.7
	−17.7	−1.9	−62.9	−74.0	−133	11.8	−128	−66.7	−107	−68.5	−22.3	−41.1
	474	439	433	438	423	394	398	391	380	402	349	347
	27.6	22.6	23.3	24.2	23.5	24.5	22.3	18.8	13.2	10.9	15.2	15.7
	97.7	88.6	80.1	76.1	73.8	69.0	70.0	70.5	69.0	69.5	69.4	67.6
	724	649	621	641	599	574	595	588	551	476	554	578
	1,943	1,731	1,686	1,695	1,527	1,591	1,525	1,498	1,407	1,337	1,449	1,470
	332	228	294	316	281	272	260	239	237	260	266	208
	234	139	213	240	208	203	190	169	168	191	197	141
Profit
	221	142	206	222	191	193	177	167	157	183	185	135
	0.0	−24.8	−42.2	0.0	0.0	0.0	0.0	12.9	0.0	0.0	0.0	0.0
	221	118	163	222	191	193	177	180	157	183	185	135
	44.4	31.3	27.5	46.6	22.2	20.6	22.5	40.2	38.8	26.4	27.8	3.5
	5.2	−114	2.1	−6.6	14.3	14.7	17.6	−13.0	−16.3	−21.8	−23.7	−5.5
	49.5	−82.9	29.6	40.0	36.5	35.3	40.1	27.3	22.5	4.6	4.1	−1.9
	0.4	1.1	−1.8	1.4	−0.5	−0.7	0.4	0.9	0.3	−0.4	−0.1	−0.5
	172	202	132	184	154	157	138	153	135	178	180	137
	172	200	134	182	154	157	137	152	134	179	181	137
	2.3	11.5	8.0	4.7	0.7	5.5	2.0	1.3	−3.3	−11.5	1.0	0.6
	175	213	140	188	154	162	140	154	131	167	181	137
	173	—	133	185	154	157	138	153	135	178	180	137
	−0.7	1.2	−1.0	−1.0	−0.8	−0.3	−0.7	−0.3	−0.2	0.0	0.0	0.0
Per share
	₹8.80	₹10.31	₹6.76	₹9.40	₹7.85	₹7.98	₹7.01	₹7.79	₹6.85	₹9.07	₹9.18	₹6.95
	₹8.80	₹10.31	₹6.76	₹9.40	₹7.85	₹7.98	₹7.01	₹7.79	₹6.85	₹9.07	₹9.18	₹6.95
Other comprehensive income — detail
	2.3	11.5	8.0	4.7	0.7	5.5	—	—	—	—	—	—
	−0.5	−2.0	2.7	−7.2	−0.5	1.6	0.1	0.3	−3.9	−13.3	−0.2	−2.0
	−0.1	−0.1	0.5	−1.3	−0.1	−0.2	—	—	—	—	—	—
	—	—	—	—	—	—	0.0	0.0	−0.7	−0.6	−0.4	0.0
	3.1	13.4	5.8	10.6	1.1	3.7	1.9	1.1	—	1.2	0.9	2.6
	0.5	0.0	0.0	0.0	0.0	0.0	—	—	—	—	—	—
	—	—	—	—	—	—	0.0	0.0	0.1	0.0	0.0	0.0
	175	−1.5	141	189	155	162	140	155	131	167	181	137
	−0.7	215	−1.1	−1.1	−0.8	−0.3	−0.8	−0.3	−0.2	0.0	0.0	0.0
Per share — as-filed variants
	₹8.80	₹10.31	₹6.76	₹9.40	₹7.85	₹7.98	₹7.01	₹7.79	₹6.85	₹9.07	₹9.18	₹6.95
	₹8.80	₹10.31	₹6.76	₹9.40	₹7.85	₹7.98	₹7.01	₹7.79	₹6.85	₹9.07	₹9.18	₹6.95
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,530	1,316	1,347	1,394	1,303	1,239	1,253	1,219	1,168	1,138	1,170	1,134
	71.2%	71.2%	71.8%	73.0%	76.2%	70.0%	74.0%	74.0%	74.8%	75.0%	71.7%	71.1%
Adjusted (ex-exceptional items) — derived
	221	142	206	222	191	193	177	167	157	183	185	135
	0.0	−24.8	−42.2	0.0	0.0	0.0	0.0	12.9	0.0	0.0	0.0	0.0
	172	226	167	184	154	157	138	142	135	178	180	137
	₹8.80	₹11.58	₹8.53	₹9.40	₹7.85	₹7.98	₹7.01	₹7.23	₹6.85	₹9.07	₹9.18	₹6.95

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

APLLTD₹782.80

Alembic Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAJANTPHARM IPCALAB TORNTPHARM ALIVUS AKUMS AGARWALEYE ADVENZYMES AARTIPHARMMcap ₹15,386 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	1,594.9	1,630.6	1,517.0	1,561.7	1,648.0	1,692.7	1,769.6	1,710.7	1,910.2	1,876.3	1,847.7	2,149.8
Other Income	10.2	2.9	3.6	2.1	16.7	9.5	14.2	6.5	6.9	15.5	25.5	14.9
Total Income	1,605.1	1,633.5	1,520.6	1,563.8	1,664.7	1,702.2	1,783.8	1,717.2	1,917.1	1,891.8	1,873.2	2,164.7
Expenses
+ Cost of Materials Consumed	413.9	317.6	337.4	405.9	393.1	446.9	426.2	431.3	463.1	448.7	404.2	517.3
+ Purchases of Stock-in-Trade	88.7	165.5	110.5	95.5	102.6	120.2	92.6	109.2	126.8	143.1	129.8	120.5
+ Changes in Inventories	-41.1	-22.3	-68.5	-107.3	-66.7	-127.6	11.8	-133.0	-74.0	-62.9	-1.9	-17.7
+ Employee Benefit Expense	347.0	349.3	401.8	379.8	391.5	397.5	393.6	422.8	437.5	432.7	438.9	473.9
+ Finance Costs	15.7	15.2	10.9	13.2	18.8	22.3	24.5	23.5	24.2	23.3	22.6	27.6
+ Depreciation & Amortisation	67.6	69.4	69.5	69.0	70.5	70.0	69.0	73.8	76.1	80.1	88.6	97.7
+ Other Expenses	578.3	554.2	475.7	551.0	588.1	595.5	573.5	599.2	641.0	621.1	648.7	723.9
Total Expenses	1,469.9	1,448.8	1,337.3	1,407.1	1,498.0	1,524.8	1,591.2	1,526.7	1,694.8	1,686.2	1,730.9	1,943.2
EBITDA	208.2	266.4	260.1	236.8	239.3	260.2	271.9	281.3	315.7	293.5	227.9	331.9
EBIT	140.7	196.9	190.6	167.8	168.8	190.2	202.9	207.6	239.6	213.4	139.3	234.2
Profit
PBT before Exceptional Items	135.1	184.6	183.2	156.7	166.7	177.4	192.6	190.6	222.3	205.6	142.3	221.5
+ Exceptional Items	0.0	0.0	0.0	0.0	12.9	0.0	0.0	0.0	0.0	-42.2	-24.8	0.0
Pretax Income	135.1	184.6	183.2	156.7	179.6	177.4	192.6	190.6	222.3	163.3	117.5	221.5
+ Current Tax	3.5	27.8	26.4	38.8	40.2	22.5	20.6	22.2	46.6	27.5	31.3	44.4
+ Deferred Tax	-5.5	-23.7	-21.8	-16.3	-13.0	17.6	14.7	14.3	-6.6	2.1	-114.2	5.2
Tax Expense	-1.9	4.1	4.6	22.5	27.3	40.1	35.3	36.5	40.0	29.6	-82.9	49.5
+ Share of Associates & JVs	-0.5	-0.1	-0.4	0.3	0.9	0.4	-0.7	-0.5	1.4	-1.8	1.1	0.4
Net Income	136.6	180.5	178.2	134.5	153.1	137.7	156.6	153.6	183.7	132.0	201.5	172.4
+ Net Income — Continuing Ops	137.1	180.5	178.6	134.2	152.3	137.3	157.3	154.1	182.3	133.8	200.4	172.0
+ Other Comprehensive Income	0.6	1.0	-11.5	-3.3	1.3	2.0	5.5	0.7	4.7	8.0	11.5	2.3
Total Comprehensive Income	137.1	181.5	166.7	131.2	154.5	139.7	162.2	154.3	188.4	139.9	213.1	174.6
Net Income to Common	136.6	180.5	178.2	134.7	153.4	138.4	156.9	154.4	184.7	133.0	—	173.1
Minority Interest	0.0	0.0	0.0	-0.2	-0.3	-0.7	-0.3	-0.8	-1.0	-1.0	1.2	-0.7
Per Share
Basic EPS	6.95	9.18	9.07	6.85	7.79	7.01	7.98	7.85	9.40	6.76	10.31	8.80
Diluted EPS	6.95	9.18	9.07	6.85	7.79	7.01	7.98	7.85	9.40	6.76	10.31	8.80
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	5.5	0.7	4.7	8.0	11.5	2.3
+ Items NOT to be Reclassified to P&L	-2.0	-0.2	-13.3	-3.9	0.3	0.1	1.6	-0.5	-7.2	2.7	-2.0	-0.5
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.2	-0.1	-1.3	0.5	-0.1	-0.1
+ Tax on Items NOT to be Reclassified — alt tag	0.0	-0.4	-0.6	-0.7	0.0	0.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	2.6	0.9	1.2	—	1.1	1.9	3.7	1.1	10.6	5.8	13.4	3.1
+ Tax on Items to be Reclassified	—	—	—	—	—	—	0.0	0.0	0.0	0.0	0.0	0.5
+ Tax on Items to be Reclassified — alt tag	0.0	0.0	0.0	0.1	0.0	0.0	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	137.1	181.5	166.7	131.4	154.7	140.5	162.4	155.1	189.5	141.0	-1.5	175.3
Comprehensive Income — Non-controlling Interests	0.0	0.0	0.0	-0.2	-0.3	-0.8	-0.3	-0.8	-1.1	-1.1	214.5	-0.7
Per Share — as-filed variants
Basic EPS — Continuing Operations	6.95	9.18	9.07	6.85	7.79	7.01	7.98	7.85	9.40	6.76	10.31	8.80
Diluted EPS — Continuing Operations	6.95	9.18	9.07	6.85	7.79	7.01	7.98	7.85	9.40	6.76	10.31	8.80
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,133.5	1,169.8	1,137.6	1,167.6	1,218.9	1,253.2	1,239.0	1,303.3	1,394.2	1,347.3	1,315.6	1,529.7
Gross Margin %	71.07	71.74	74.99	74.77	73.96	74.03	70.02	76.18	72.99	71.81	71.20	71.16
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	135.1	184.6	183.2	156.7	166.7	177.4	192.6	190.6	222.3	205.6	142.3	221.5
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	12.9	0.0	0.0	0.0	0.0	-42.2	-24.8	0.0
Net Income Adj (tax-effected)	136.6	180.5	178.2	134.5	142.2	137.7	156.6	153.6	183.7	166.5	226.3	172.4
EPS Adj	6.95	9.18	9.07	6.85	7.23	7.01	7.98	7.85	9.40	8.53	11.58	8.80
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Filed Debt Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.23	0.22	0.27	0.25	0.24	0.28
Filed Dscr	—	—	—	—	—	—	8.83	9.08	10.23	7.93	5.11	7.63
Filed Iscr	—	—	—	—	—	—	8.83	9.08	10.23	7.93	6.26	9.04
Paid Up Equity Capital	39.3	39.3	39.3	39.3	39.3	39.3	39.3	39.3	39.3	39.3	39.3	39.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Alembic Pharmaceuticals Q2 FY27 results date

Alembic Pharmaceuticals (NSE: APLLTD) will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, according to the board-meeting notice it filed on 28 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹173 crore, up 12.1% from ₹154 crore in Q1 FY26 and down 14.1% from ₹202 crore in Q4 FY26. Revenue from operations was ₹2,150 crore, up 25.7% year on year and up 16.3% from the previous quarter.

Board-meeting notice filed: 28 October 2026
Q2 FY26 results (a year earlier): 4 November 2025
Q1 FY27 results (the latest): 4 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 4 November 2026Wednesday · notice filed 28 Oct
Q1 FY27 net profit: ₹173 Cr+12.1% vs Q1 FY26−14.1% vs Q4 FY26
Q1 FY27 revenue: ₹2,150 Cr+25.7% vs Q1 FY26+16.3% vs Q4 FY26
Q1 FY27 operating margin: 10.9%−1.2 pts vs Q1 FY26+3.4 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹185 CrRevenue ₹1,910 Cr
Q1 FY27 EPS (basic): ₹8.80

Questions

When will Alembic Pharmaceuticals announce its Q2 FY27 results?

On 4 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 28 October 2026). Last year it reported Q2 FY26 on 4 November 2025.

What will Alembic Pharmaceuticals' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹185 crore and revenue from operations ₹1,910 crore. The latest quarter, Q1 FY27, had a net profit of ₹173 crore and revenue of ₹2,150 crore.

What was Alembic Pharmaceuticals' revenue in FY26?

Revenue from operations was ₹7,345 crore in FY26 (April 2025–March 2026), up 10.1% from ₹6,672 crore in FY25. It was ₹6,229 crore in FY24 and ₹5,653 crore in FY23: up 29.9% over three years, 9.1% a year on average.

What were Alembic Pharmaceuticals' Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹173 crore, up 12.1% from ₹154 crore in Q1 FY26 and down 14.1% from ₹202 crore in Q4 FY26. Revenue from operations was ₹2,150 crore, up 25.7% year on year and up 16.3% from the previous quarter.

How has Alembic Pharmaceuticals' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹185 crore in Q2 FY26, ₹133 crore in Q3 FY26, ₹202 crore in Q4 FY26 and ₹173 crore in Q1 FY27. That is ₹692 crore over the four quarters, up 14.8% from ₹603 crore in the four quarters before. Revenue from operations: ₹1,910 crore, ₹1,876 crore, ₹1,848 crore and ₹2,150 crore.

What was Alembic Pharmaceuticals' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹675 crore in FY26 (April 2025–March 2026), up 15.7% from ₹583 crore in FY25. It was ₹616 crore in FY24 and ₹342 crore in FY23: up 97.3% over three years, 25.4% a year on average.

Where do these Alembic Pharmaceuticals figures come from?

From Alembic Pharmaceuticals' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.